Publications by authors named "Dominique Y Atmodjo"
Article Synopsis
- In the REGEN-COV adaptive trial, a combination of monoclonal antibodies significantly reduced both viral load and hospital visits in COVID-19 patients compared to a placebo.
- In the phase 3 trial, outpatients with COVID-19 received either REGEN-COV or placebo, leading to a substantial decrease in hospitalization or death rates (1.3% in the 2400-mg group vs. 4.6% in placebo).
- The treatment also expedited symptom resolution by an average of 4 days and effectively reduced viral load more rapidly than the placebo across various patient subgroups.
Background: The authors investigated thermal injury depth, inflammation, and scarring in human abdominal skin by comparing the histology of incisions made with a standard "cold" scalpel blade, conventional electrosurgery, and the PEAK PlasmaBlade, a novel, low-thermal-injury electrosurgical instrument.
Methods: Approximately 6 and 3 weeks before abdominoplasty, full-thickness incisions were created in the abdominal pannus skin of 20 women, using a scalpel (scalpel), the PlasmaBlade, and a conventional electrosurgical instrument. Fresh (0-week) incisions were made immediately before surgery.